Myomo Q3 revenue rises 22% to record high
MYO•Myomo’s third-quarter revenue rose 22% year over year to a record, and the company achieved adjusted EBITDA breakeven. It narrowed full-year 2026 revenue guidance to $46 million-$47 million and expects cash burn below $2 million in the second half of 2026.
1. Revenue and profitability
Myomo said third-quarter revenue rose 22% year over year to a record high. The company achieved breakeven adjusted EBITDA and reported a loss per share of $0.10.
2. Growth drivers and outlook
Revenue units increased 19% and average selling price rose 2%. Referrals from provider networks and the VA accounted for 54% of third-quarter revenue. Myomo narrowed its full-year 2026 revenue guidance to $46 million-$47 million, the upper half of its prior range, reiterated its expectation for full-year operating leverage, and expects cash burn below $2 million in the second half of 2026. Gross margin expansion was driven by material cost reductions and improved fixed-cost absorption from higher volume.
